Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Drugs Controller General of India (DCGI) approved India's first Quadri-valent Human Papillomavirus vaccine (qHPV) against cervical cancer.
The new centre has been established in remote Dombang, abutting the LAC strong, and is located at a height of 10,040 ft. in Sikkim shares a 220 km front of the India-China LAC.
EXAMIANS